Clonidine in the treatment of severe hypertension. 1973

J Raftos, and G E Bauer, and R G Lewis, and G S Stokes, and A S Mitchell, and A A Young, and I Maclachlan

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D006974 Hypertension, Malignant A condition of markedly elevated BLOOD PRESSURE with DIASTOLIC PRESSURE usually greater than 120 mm Hg. Malignant hypertension is characterized by widespread vascular damage, PAPILLEDEMA, retinopathy, HYPERTENSIVE ENCEPHALOPATHY, and renal dysfunction. Malignant Hypertension
D006977 Hypertension, Renal Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN. Hypertensions, Renal,Renal Hypertension,Renal Hypertensions
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008750 Methyldopa An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. Methyldopate,alpha-Methyldopa,Aldomet,Alphamethyldopa,Apo-Methyldopa,Dopamet,Dopegit,Dopegyt,Dopergit,Hydopa,Meldopa,Nu-Medopa,Sembrina,alpha-Methyl-L-Dopa,Apo Methyldopa,Nu Medopa,alpha Methyl L Dopa,alpha Methyldopa
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002561 Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others. Brain Vascular Disorders,Intracranial Vascular Disorders,Vascular Diseases, Intracranial,Cerebrovascular Diseases,Cerebrovascular Insufficiency,Cerebrovascular Occlusion,Brain Vascular Disorder,Cerebrovascular Disease,Cerebrovascular Disorder,Cerebrovascular Insufficiencies,Cerebrovascular Occlusions,Disease, Cerebrovascular,Diseases, Cerebrovascular,Insufficiencies, Cerebrovascular,Insufficiency, Cerebrovascular,Intracranial Vascular Disease,Intracranial Vascular Diseases,Intracranial Vascular Disorder,Occlusion, Cerebrovascular,Occlusions, Cerebrovascular,Vascular Disease, Intracranial,Vascular Disorder, Brain,Vascular Disorder, Intracranial,Vascular Disorders, Brain,Vascular Disorders, Intracranial
D003000 Clonidine An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION. Catapres,Catapresan,Catapressan,Chlophazolin,Clofelin,Clofenil,Clonidine Dihydrochloride,Clonidine Hydrochloride,Clonidine Monohydrobromide,Clonidine Monohydrochloride,Clopheline,Dixarit,Gemiton,Hemiton,Isoglaucon,Klofelin,Klofenil,M-5041T,ST-155,Dihydrochloride, Clonidine,Hydrochloride, Clonidine,M 5041T,M5041T,Monohydrobromide, Clonidine,Monohydrochloride, Clonidine,ST 155,ST155
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary

Related Publications

J Raftos, and G E Bauer, and R G Lewis, and G S Stokes, and A S Mitchell, and A A Young, and I Maclachlan
December 1983, The Journal of the Association of Physicians of India,
J Raftos, and G E Bauer, and R G Lewis, and G S Stokes, and A S Mitchell, and A A Young, and I Maclachlan
February 1976, Lancet (London, England),
J Raftos, and G E Bauer, and R G Lewis, and G S Stokes, and A S Mitchell, and A A Young, and I Maclachlan
October 1977, Journal of postgraduate medicine,
J Raftos, and G E Bauer, and R G Lewis, and G S Stokes, and A S Mitchell, and A A Young, and I Maclachlan
January 1979, Acta paediatrica Belgica,
J Raftos, and G E Bauer, and R G Lewis, and G S Stokes, and A S Mitchell, and A A Young, and I Maclachlan
January 1979, Acta paediatrica Belgica,
J Raftos, and G E Bauer, and R G Lewis, and G S Stokes, and A S Mitchell, and A A Young, and I Maclachlan
January 1992, The American journal of the medical sciences,
J Raftos, and G E Bauer, and R G Lewis, and G S Stokes, and A S Mitchell, and A A Young, and I Maclachlan
January 1980, Journal of cardiovascular pharmacology,
J Raftos, and G E Bauer, and R G Lewis, and G S Stokes, and A S Mitchell, and A A Young, and I Maclachlan
September 1976, The Journal of the Association of Physicians of India,
J Raftos, and G E Bauer, and R G Lewis, and G S Stokes, and A S Mitchell, and A A Young, and I Maclachlan
January 1977, Harefuah,
J Raftos, and G E Bauer, and R G Lewis, and G S Stokes, and A S Mitchell, and A A Young, and I Maclachlan
February 1971, British medical journal,
Copied contents to your clipboard!